<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal CancerChristos S. Karapetis, John Zalcberg, Shirin Khambata‐Ford et al.|New England Journal of Medicine|2008Cited by 3.6k
Cetuximab for the Treatment of Colorectal CancerDerek J. Jonker, Malcolm J. Moore, Chris J. O’Callaghan et al.|New England Journal of Medicine|2007Cited by 1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Juan Manuel O’Connor, Guillermo Ariel Mendez et al.|The Lancet|2018Cited by 1.3k
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary AdenocarcinomaJohn P. Neoptolemos, Malcolm J. Moore, Trevor F. Cox et al.|JAMA|2012Cited by 590
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C. Tebbutt, Timothy Price|Journal of Clinical Oncology|2010Cited by 417